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Abstract Mesenchymal Stem Cells (MSCs) have high
therapeutic value for regenerative medicine and tissue
engineering due to their differentiation potential and non-
immunogenic characteristics. They are also considered as
an effective in vivo delivery agent because of their ability to
migrate to the site of injury. A major roadblock in their use
for cell-based therapies is their rareness in vivo. Therefore,
it is important to obtain increased number of functional
MSCs in vitro in order to have adequate numbers for
therapeutic regiments. We aimed to investigate the role of
estrogen and its mechanism in obtaining more MSCs.
MSCs were isolated from female and ovariectomized rats
and cultured in the presence and absence of 10−7 M
estrogen. In the presence of estrogen, not only their CFU-
F activity increased but also apoptotic rate decreased as
shown by TUNEL staining leading to obtain more MSCs.
Also the number of the cells in the colonies increased upon
estrogen treatment. To reveal the mechanism of this effect,
we focused on Bcl-2 family of proteins. Our immunoblot-
ting experiments combined with knockdown studies sug-
gested a critical role for anti-apoptotic Bcl-xL and Bcl-2.
Estrogen treatment up regulated the expression Bcl-xL and
Bcl-2. When we knocked down the expression of bcl-xL
and bcl-2, MSCs lacking these genes showed an increase in
the apoptotic rate in contrast to normal MSCs following
estrogen treatment. Therefore, estrogen treatment will be of
great advantage for cell-based therapies in order to get more
functional MSCs and may provide opportunities to develop
new strategies for debilitating diseases.
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Introduction
Increased human lifespan has brought the concept of a
better life quality, since the body functions and health
conditions decline with time. Identifying with the pioneer-
ing studies of Friedenstein [1], mesenchymal stem cells
(MSCs) have demonstrated great potential to tackle these
problems. Multipotent MSCs have potential to differentiate
into tissue-specific cell types such as osteocytes, adipo-
cytes, chondrocytes, myoblasts, cardiomyocytes [1–3].
MSCs emerge as an important player of cellular-based
therapies in wide variety of pathologies such as neurode-
generative and cardiovascular diseases, diabetes, and cancer
due to their ability to migrate in vivo to promote
regeneration of damaged tissue, treat inflammation, and
promote angiogenesis without inducing immune reaction
[4–7]. Besides being a future promise for many disease
treatments, there are also some handicaps in their applica-
tions. One major roadblock is their rareness and the fact
that they constitute a very small population of nucleated
cells in the bone marrow [8]. Their number has to be
increased before they can be used for therapeutic purposes.
Similar to stem cells, estrogen hormone can also be
accepted as a key factor in the preservation of life
standards. Estrogen is mainly responsible for female sexual
features but also influences many physiological processes
in mammals including cellular proliferation and apoptosis
[9, 10]. In humans, increased incidence of osteoporosis and
coronary heart diseases after menopause suggests the
involvement of estrogen in these disorders [11, 12]. Since
MSCs differentiate into bone and muscle cells, the effect of
F. Ayaloglu-Butun : E. Terzioglu-Kara : Z. Tokcaer-Keskin :
K. C. Akcali (*)




Stem Cell Rev and Rep (2012) 8:393–401
DOI 10.1007/s12015-011-9292-0
estrogen on MSCs is also critical. Understanding the
mechanism of their interaction is vital for obtaining the
maximum efficiency from this collaboration. Apoptotic
pathways, which are conserved throughout evolution, are
strong candidates for this cooperation. Estrogen has a dual
role on apoptosis; it can both stimulate and inhibit
apoptosis depending on the type of cell, the duration and
amount of estrogen and the downstream target signaling
pathway. Estrogen promotes apoptosis in osteoclasts,
thymocytes and neurons [13–16]. On the other hand, it
has antiapoptotic effect on osteocyte, umbilical vein
endothelial cells, hippocampal neurons and breast cancer
cell lines [17–20].
Although the mechanism of the apoptotic or antiapop-
totic function of estrogen is not always through the same
pathway, regulation through the bcl-2 family of genes is a
major candidate in this process. The members of the Bcl-2
family of proteins determine the life-or-death of a cell by
controlling the release of mitochondrial apoptogenic fac-
tors, cytochrome c and apoptosis inducing factors (AIF),
which activate the downstream executional phases, includ-
ing the activation of the caspases [21, 22]. Estrogen
increases the expression of anti-apoptotic but decreases
the expression of pro-apoptotic bcl-2 family of genes [19,
23, 24]. The effect of estrogen on the expression of bcl-xL
and bcl-2 is mediated through estrogen response element
(ERE) sites of these genes [19, 23]. In addition, estrogen
can also affect the expression of Bcl-2 family of genes
through the non genomic pathway which involves the
phosphorylation of the proteins [24]. Regardless of the
mechanism, it is evident that estrogen has a crucial role in
apoptotic regulation.
The present study was undertaken to investigate the
molecular mechanisms of estrogen during MSC mainte-
nance. In order to explain the mechanism of the action of
estrogen, we hypothesize that estrogen differentially regu-
lates the expression of bcl-2 family of genes and this
control results in obtaining more MSC by inhibiting
apoptosis.
Material and Methods
Isolation and Culture of MSCs
MSCs were obtained from female and ovariectomized
female 9-week old, 280–300 g Sprague–Dawley rats. The
animals were permitted unlimited access to food and water
at all times and were housed under controlled environmen-
tal conditions (22°C) with a 12-hour light and 12 h dark
cycle in the animal holding facility of the Department of
Molecular Biology and Genetics at the Bilkent University.
This study protocol complied with Bilkent University’s
guidelines on humane care and use of laboratory animals.
Bone marrow heterogeneous cell population was collected
from the femur and tibia by flushing with a 5 mL syringe
containing 10% FBS (Hyclone, Logan, UT, USA) in
DMEM (Invitrogen, Paisley, UK) after the rats were
sacrificed by cervical dislocation. The cells were cultured
in plastic culture dishes with Mesencult Media (StemCell
Technology, Vancouver, Canada) with 20% supplement
(StemCell Technology) and a 1% penicillin/streptomycin
solution (Hyclone) in a 5% CO2 incubator at 37°C. The
next day, the media of the tissue culture plates were
changed and the non-adherent cells were removed. The
media of the cells were changed every 4 days, after washing
with sterile 1x PBS prior to the change. For the estrogen
treatment, MSCs were cultured with 10−7 M estrogen (17 ß-
estradiol, Sigma, MO, USA).
Colony-Forming Assay
After washed in 1x PBS and air dried, MSCs were fixed
with cold methanol for 5 min. The cells were washed again
in a 1x PBS buffer and stained with giemsa (Carlo Erba,
Milano, Italy) for 5 min. The reaction of the giemsa
staining was stopped by the addition of tap water. The
number of colonies was counted under light microscope.
In Situ Analysis of DNA Fragmentation (TUNEL)
DNA fragmentation was detected in situ by TdT- (terminal
deoxynucleotidyl transferase) mediated fluorescein-dUTP
labeling kit (Roche Diagnostics, Mannheim, Germany).
Cells were fixed in 4% paraformaldehyde in PBS for
20 min at room temperature and then washed in PBS for
30 min. After incubating with a permeabilisation solution
(0.1% Triton X-100, 0.1% sodium citrate) for 2 min on ice,
50 μl of TUNEL reaction mixture was put into each sample
and incubated for 1 h at 37°C in the dark in a humidified
chamber. Slides were then directly analyzed by fluores-
cence microscopy. For evaluation by fluorescence micros-
copy, we used an excitation wavelength in the range of
450–500 nm and detection in the range of 515–565 nm. As
negative control, we incubated the samples in the absence
of terminal deoxynucleotidyl transferase. For positive
controls, the samples were first treated with DNase I
(1,000 U/ml in 50 mM Tris–HCl, pH 7.5, 1 mg/ml BSA)
for 10 min at 20°C to induce DNA strand breaks prior to
labeling procedures and then incubated with 50 μl of
TUNEL reaction mixture.
Total RNA Isolation and Reverse Transcription
MSCs were trypsinized and the total cellular RNA was
isolated from the precipitate by using the RNeasy Mini kit
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(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol, with additional DNase treatment. The cDNAs
were synthesized from the total RNA samples with the
DyNAmo cDNA synthesis kit (Finnzymes, Espoo, Finland)
according to the manufacturer’s protocol.
RT-PCR
cDNA amplification for bcl2, bcl-xL, CD90, CD71, CD45,
CD34, CD29, MMP12, GAPDH, and β-Actin were per-
formed by using DyNAzyme II (Finnzymes). The primers
and conditions of amplification indicated in Table 1 and 2
respectively.
Protein Isolation and Quantification
MSCs were scraped from the cell culture plates in 1x PBS
and the precipitate was treated with a lysis buffer containing
0.05 M Tris HCl, 1x protease inhibitor, 0.25 M NaCl and
1% (v/v) IGEPAL for 30 min on ice. Then the lysate was
centrifugated for 20 min at 13,000 rpm and 4°C. Protein
concentrations of supernatants were determined with
Bradford protein assay as described [25].
Western Blotting
The proteins were separated on 10% SDS-PAGE and
transferred to a polyvinylidene fluoride membrane. The
membrane was blocked with blocking solution for 2 h at
room temperature and was incubated in antibody solution at
the concentration of 1:500 (for Bcl-xL, Bak, Bcl-2, Bax);
1:200 (for ERα, ERß) and 1:1000 for Actin for o/n at 4°C.
Then the secondary antibody, anti-Rabbit-HRP were ap-
plied for 1 h in blocking solution at a concentration of
1:1000. Finally, Super Signal West Femto Maximum
Sensitivity Substrate (Thermo Scientific, IL, USA) was
applied to the membrane for 4 min and placed in an X-ray
film cassette and developed. All antibodies, except for anti-
Rabbit-HRP, were purchased from Santa Cruz (Santa Cruz,
CA, USA).
Transfection of bcl-2 and bcl-xL shRNA
shRNA of bcl-2 and bcl-xL were purchased from Open-
biosystems, (AL,USA) and prepared according to the
manufacturer’s protocol. 1 μg Bcl-2 and Bcl-xL shRNA
was added to 100 μL serum free, antibiotic free DMEM-LG
(HyClone). In another tube 4 μL and 3 μL transfection
reagent Dharmafect (Thermo Scientific) was diluted with
196 μL and 197 μL serum free antibiotic free DMEM-LG
for Bcl-2 and Bcl-xL respectively. After 5 min of incuba-
tion, the contents of shRNA and transfection reagent
containing tubes were mixed and incubated at room
temperature for 20 min. 1,200 μL antibiotic free complete
DMEM-LG was added to the mixture. The cells were
washed with 1x PBS and then the transfection mixture was
added. DMEM-LG and transfection reagent only was given
to the cells as two types of control. Next day the medium
Table 1 Primers and the product size of the genes
gapdh forward 5′-CCTCCTCATTGACCTCAACTAC -3′ 210 bp
reverse 5′-CATGGTGGTGAAGACGCCAG-3′
bcl-2 forward 5′-CCTGGCATCTTCTCCTTC-3′ 584 bp
reverse 5′-TGCTGACCTCACTTGTGG-3′
bcl-xL forward 5′-TCAATGGCAACCCTTCCTGG-3′ 346 bp
reverse 5′-ATCCGACTCACCAATACCTG-3′
beta actin forward 5'-CTGGCCTCACTGTCCACCTT- 3' 65 bp
reverse 5'-GGGCCGGACTCATCGTACT- 3'
CD 90 forward 5′- CCAGTCATCAGCATCACTCT- 3′ 374 bp
reverse 5′- AGCTTGTCTCTGATCACATT- 3′
CD 34 forward 5′- TGTCTGCTCCTTGAATCT -3′ 281 bp
reverse 5′- CCTGTGGGACTCCAACT- 3′
CD 71 forward 5′- ATGGTTCGTACAGCAGCAGA- 3′ 182 bp
reverse 5′- CGAGCAGAATACAGCCATTG- 3′
CD 29 forward 5′-ACTTCAGACTTCCGCATTGG -3′ 190 bp
reverse 5′- GCTGCTGACCAACAAGTTCA- 3′
CD 45 forward 5′- ATGTTATTGGGAGGGTGCAA-3′ 175 bp
reverse 5′- AAAATGTAACGCGCTTCAGG-3′
Mmp 12 forward 5′- GGCAACTGGACACCTCAACT -3′ 382 bp
reverse 5′- GTCCAGGTTTCTGCCTCATC -3′
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was changed to their normal media. 4 days after transfec-
tion, RNA isolation and TUNEL assays were performed.
Adipogenic Differentiation
An adipogenic induction medium was prepared freshly by
adding 1 μM dexamethasone (Sigma), 10 μg/ml insulin
(Sigma), 100 μM indomethacin (Sigma) and 0.5 mM
IBMX to LG-DMEM (HyClone), containing 1x penicillin-
streptomycin (HyClone) and 10% FBS (HyClone). The
MSCs were cultured for 21 days, changing the medium
every 2 days with freshly prepared medium. After 21 days
the cells were fixed with 4% paraformaldehyde and stained
with Oil Red O (Sigma).
Osteogenic Differentiation
An osteogenic induction medium was prepared by freshly
adding 0.1 μM dexamethasone (Sigma), 0.2 mM ascorbic
acid 2-phosphate (Sigma) and 10 mM glycerol-2-phosphate
(Sigma) to LG-DMEM (HyClone), containing 1x
penicillin-streptomycin (HyClone) and 10% FBS
(HyClone). The MSCs were cultured for 21 days, changing
the medium every 2 days with freshly prepared medium.
After 21 days the cells were fixed with 10% formaldehyde
and stained with Von Kossa (Sigma).
Statistical Analysis
All data are expressed as means ± SD. Data were analyzed
by performing paired t-test using Minitab Statistical
Software ® (State College, Pennsylvania, USA). A value
of P<0.05 was considered to be statistically significant.
Results
We first examined the characteristics of MSCs isolated from
normal and ovariectomized rats and cultured in the absence
or presence of 10−7 M estrogen (Fig. 1). We repeated our
experiments three times with three animals per group. By
using RT-PCR, we showed that all of the experimental
groups were positive for mesenchymal stem cell markers
(CD29, CD71 and CD90) and negative for hematopoietic
cell markers (CD34, CD45) (Fig. 1a). We also examined the
expression levels of ER α and ER β in our experimental
groups. Our western blot data showed that both ER α and
ER β were expressed in MSCs isolated from normal and
ovariectomized rats (Fig. 1b). We also showed that upon
estrogen addition, the expression of an estrogen responsive
gene, MMP12 increased both in normal and ovariectomized
animals (Fig. 1c).
We then investigated the effect of estrogen treatment on
MSCs’ CFU-F activities and differentiation capabilities
(Fig. 2). The results of our CFU-F assay showed that
estrogen treatment caused an increase in the colony
numbers of MSCs that were isolated from both normal
and ovariectomized rats (Fig. 2a). Moreover, the number of
the cells in the colonies also increased when MSCs were
treated with estrogen (Fig. 2a). When MSCs isolated from
both normal and ovariectomized animals were put into
adipogenic and osteogenic differentiation medium, they
Table 2 PCR conditions for the genes
Genes Initial denaturation Denaturation Annealing Extension Cycles Final extension




23 72°C, 5 min




36 72°C, 5 min




31 72°C, 5 min




25 72°C, 5 min




30 72°C, 5 min




30 72°C, 5 min




35 72°C, 5 min




29 72°C, 5 min




23 72°C, 5 min




28 72°C, 5 min
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were able to form adipocytes and osteocytes (Fig. 2b). Our
results revealed that the capacity of differentiation into
adipocyte lineage was to a lesser degree when MSCs were
incubated in the presence of estrogen (Fig. 2b (ii vs iv)).
Since the cell number may be directly related to the
involvement of apoptosis, we then examined the effect of
estrogen on the apoptotic rate of MSCs (Fig. 3). Apoptotic
rate was calculated as the ratio of TUNEL (+) cells to the
Fig. 1 Characterization of bone marrow-derived mesenchymal stem
cells. a The expression of the markers of MSCs (CD90, CD29 and
CD71) and hematopoietic cells (CD34, CD45) by RT-PCR. b Protein
expression of ERα and ERβ determined by Western blot. Actin
expression was used as loading control. c mRNA expression estrogen
regulatory gene, MMP12 determined by RT-PCR. Actin expression
was used as loading control. (F: MSCs obtained from female rats; F
+e: MSCs obtained from female rats treated with estrogen; Ovx:
MSCs obtained from ovariectomized rats; Ovx+e: MSCs obtained
from ovariectomized rats treated with estrogen.)
Fig. 2 Effect of estrogen on the bone marrow-derived mesenchymal
stem cells. a CFU activities and the number of the cells in a colony *
indicates p≤0.05; b Differentiation capacities of MSCs in the absence
(i, iii) and presence (ii, iv) of estrogen. MSCs were stained with Oil
Red O to determine adipogenic differentiation (i, ii), with Von Kossa
staining to determine osteogenic differentiation (iii, iv)
Stem Cell Rev and Rep (2012) 8:393–401 397
total number of cells. Addition of estrogen decreased the
number of TUNEL (+) MSCs isolated both from normal
(Fig. 3a and b) and ovariectomized rats (Fig. 3c and d). Our
results suggested that estrogen protects MSCs from apo-
ptosis (Fig. 3e).
In order to understand the molecular mechanism of
estrogen action on apoptosis, we focused on Bcl-2 family of
proteins. We examined the expressions of both anti-
apoptotic (Bcl-xL, Bcl-2) and pro-apoptotic (Bak and Bax)
members of this family (Fig. 4). Our western blot experi-
ments revealed that addition of estrogen caused an increase
in the expression of anti-apoptotic members of Bcl-2 family
of proteins (Fig. 4a). On the other hand, we did not observe
any change in the expression of pro-apoptotic members
(Fig. 4b). We knocked down the expression of bcl-2 and
bcl-xL by using shRNA to reveal that the anti-apoptotic
effect of estrogen on MSCs was through these genes
(Fig. 5a) and checked the effect of this silencing on the
apoptotic rates of MSCs determined by TUNEL assay
(Fig. 5b,c). Our results showed that the decreasing effect of
estrogen on apoptosis in non-transfected MSCs reversed
after transfecting the cells with shRNA of either bcl-2or
bcl-xL. The percentage of the apoptotic cells increased
when bcl-xL or bcl-2 shRNA transfected cells cultured even
in the presence of estrogen (Fig. 5b and c respectively).
Discussion
Stem cells are the new hope for the humans since they have
the potential to differentiate to several types of cells and
tissues. They are future candidates for many therapeutic
applications and can be the cure for many diseases such as
neurodegenerative diseases, diabetes, and cancer [26].
Estrogen also influences the quality of life both in men
and women and is a strong candidate in the maintenance of
life standards. Estrogen has important effects on blood
vessels, neurotransmitter release, sexual behaviour, bone
structure, cognitive function and spermatogenesis and
regulates many pathways vital for the homeostasis [27,
28]. Therefore our understanding of its importance should
not be limited only to the reproductive system. In this study,
we aimed to understand the role of estrogen on the MSCs
which emerge as an important player of cellular-based
therapies due to lack of immunogenicity and ethical
problems.
Since we focused on the role of estrogen on MSCs, we
first examined the expression status and functionality of ER
α and ER β on these cells (Fig. 1b and c). Bone marrow is
one of the target tissues of estrogen and osteoblasts,
Fig. 3 In situ analysis of DNA fragmentation (TUNEL) of MSCs.
MSCs were isolated from normal (a, b) and ovariectomized (c, d) rats.
Cells were cultured in the absence (a, c) and presence (b, d) of
estrogen. e Percentage of apoptotic cells. * indicates p≤0.05
Fig. 4 Expression of a anti-apoptotic and b pro-apoptotic members of
Bcl-2 family of proteins in MSCs determined by Western blot. Actin
expression was used as loading control (F: MSCs obtained from
female rats; F+e: MSCs obtained from female rats treated with
estrogen; Ovx: MSCs obtained from ovariectomized rats; Ovx+e:
MSCs obtained from ovariectomized rats treated with estrogen)
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osteocytes, osteoclasts, T cells and B cells in human and
mouse bone marrow express both ERα and ERβ [29]. Our
results showed that rat bone marrow-derived MSCs also
express ERα and ERβ (Fig. 1b). Our data regarding to the
expression of estrogen regulated gene, MMP12 [30],
suggest that these receptors are functional. MSCs isolated
both from normal and ovariectomized rats increased the
expression of MMP12 upon estrogen addition (Fig. 1c).
Estrogen addition to the culture media increased the
number of colonies both in the normal and ovariectomized
group which suggests that estrogen has an increasing effect
on the number of functional MSCs both in normal and
estrogen deprived conditions (Fig. 2). In addition the
number of cells in a colony was more when cells were
treated with estrogen. These results are also in accordance
with a previous study which showed that the number of
MSCs obtained from ovariectomized animals was increased
upon estrogen addition [31].
In addition, we observed that the differentiation potency of
MSCs into adipocyte but not to osteocytes could be affected
with estrogen. Estrogen has been shown to have an important
role on adipocyte metabolism [32] and our results provided
support that this effect might also be at the level of
differentiation. It has been reported that MSCs from
osteoporotic post-menopausal women showed an increase
in PPARγ expression and thus an increase in adipocytes [33].
In addition, serum from post menopausal in comparison to
serum from pre-menopausal women, were able to induce
adipogenic differentiation in a human bone progenitor cell
clone (hOP 7) derived from bone marrow [34]. Therefore, in
the absence of estrogen, MSCs’ adipocyte differentiation
capacity increased suggesting that estrogen influences adipo-
genesis and this may explain why post-menopausal women
gain weight and develop diseases associated with obesity.
Molecular mechanism of this effect in MSCs is not known
and clearly warranted new experiments.
The proliferative effect of estrogen has been shown on
rat bone marrow-derived MSCs before [35]. In contrast to
proliferation, the effect of estrogen on the maintenance of
rat bone marrow-derived MSCs from normal animals have
not been reported. We examined the effect of estrogen in the
apoptotic rates of MSC by in situ cell death assay. When the
ratios of apoptotic cells to total cells in the colonies were
compared, the addition of estrogen decreased the death
ratios in the normal and ovariectomized groups suggesting
that estrogen is effective in the process of MSC colony
formation both by decreasing apoptosis in addition to
increasing proliferation. It is important to note that in our
system, we did not induce apoptosis with any factor
therefore we evaluated the spontaneous physiological
apoptosis of bone marrow-derived MSCs.
In order to understand the molecular mechanism of the
decrease in apoptosis upon estrogen administration, we
focused on the Bcl-2 family of proteins. The Bcl-2 protein
family consists of both pro- and anti-apoptotic members.
The founder of the family, Bcl-2, was first identified in
1985 as the part of the most common translocation in
human B-cell lymphoma [36]. After the identification of
Bcl-2 as a survival factor, many different homologues were
identified and characterized [37]. Recent reports established
the effect of estrogen on the expression of Bcl-2 family of
Fig. 5 Effect of silencing the expression of bcl-xL and bcl-2 on the
apoptotic rates. a Expression of bcl-2 and bcl-xL determined by RT-
PCR in MSCs transfected with and without shRNA of bcl-2 and bcl-
xL. T: control vector transfection. Expression of GAPDH was used as
loading control. b Percentage of apoptotic cells after MSCs were
transfected with bcl-xL shRNA determined by TUNEL assay. *
indicates p≤0.05. c Percentage of apoptotic cells after MSCs were
transfected with bcl-2 shRNA determined by TUNEL assay
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proteins in other systems [19, 23, 24]. Our immunoblotting
and knock down data also suggested that estrogen controls
the apoptosis by regulating the expression of Bcl-2 family
of proteins in rat MSCs (Fig. 4). These results are in
correlation with other studies performed on other stem cells
like skin stem cells, HSCs, and epithelial stem cells where
apoptosis and members of the bcl-2 family of genes were
shown to be important in the differentiation and regulatory
pathways [38–40]. When we cultured MSCs in the presence
of estrogen, the expression of anti-apoptotic Bcl-2 and Bcl-
xL were increased. This effect was more evident when
MSCs were isolated from normal female rats than the
ovariectomized rats. The Bcl-2 protein expression did not
increase in the ovariectomized group, which might be
explained by the loss of estrogen susceptibility due to a
long period in an estrogen deprived environment. On the
other hand, the expression of proapoptotic Bak and Bax
proteins did not change with estrogen treatment. To confirm
the role of anti-apoptotic Bcl-2 family of proteins on
MSCs’ maintenance, we silenced the expression of Bcl-2
and Bcl-xL. Our data showed that upon knocking down the
expression of these genes, we observed the inhibition of
apoptosis (Fig. 5) and CFU-F capacity of (data not shown)
in MSCs isolated from normal and ovariectomized rats,
suggesting a critical role for these genes in the estrogen
regulation of apoptosis.
In conclusion, we have shown that apoptosis is one of
the main regulatory mechanisms in the maintenance of
MSCs. Bcl-2 and Bcl-xL are important proteins in this
regulation and estrogen affects the expression rates of these
proteins, increasing the colonies and decreasing the
apoptotic rate. Modulation of with estrogen may help to
obtain more MSCs which might be important for clinical
applications.
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